# Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%

> **NCT07215962** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 300 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **BIOLOGICAL:** Nivolumab + ipilimumab
- **BIOLOGICAL:** Nivolumab + ipilimumab + platinum-based chemotherapy
- **BIOLOGICAL:** Immuno-oncology-based therapy (excluding nivolumab-based regimens) with chemotherapy
- **BIOLOGICAL:** Other dual-immuno-oncology therapy with chemotherapy

## Key facts

- **NCT ID:** NCT07215962
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-22
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215962, "Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07215962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*